A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients

Trial Profile

A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients

Completed
Phase of Trial: Phase II/III

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic asthma; Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 02 May 2014 Results published in the Journal of Allergy and Clinical Immunology.
    • 16 Aug 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top